Enanta Pharmaceuticals Inc
NASDAQ:ENTA 4:00:00 PM EDT
| Market Cap (Intraday) | 341.68M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $16.36 |
| 50-Day MA | $14.57 |
| 200-Day MA | $13.16 |
Enanta Pharmaceuticals Inc Stock, NASDAQ:ENTA
500 Arsenal Street, Watertown, Massachusetts 02472
United States of America
Phone: +1.617.607.0800
Number of Employees: 145
Description
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.